|
|
Vaccine Detail
|
Pexastimogene-devacirepvec Vaccine |
| Vaccine Information |
- Vaccine Name: Pexastimogene-devacirepvec Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007136
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: (Aarntzen et al., 2012) hGM-CSF ID:1437
- GM-CSF (human)
gene engineering:
- Type: Recombinant protein preparation
- Description: [gene ID: 1437] CSF2 colony stimulating factor 2 [ Homo sapiens (human) ]
- Detailed Gene Information: Click Here.
- Preparation: Pexa-Vec is a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered to express the transgenes human granulocyte-macrophage colony-stimulating factor (GM-CSF) and β-galactosidase (Moehler et al., 2019).
- Description: This is for Ovarian Cancer (NCT02562755).A thymidine kinase-deleted vaccinia virus expressing human GM-CSF (hGM-CSF) with oncolytic activity. Upon intratumoral or intravenous administration, pexastimogene-devacirepvec may selectively infect and lyse tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the thymidine kinase gene increases the tumor selectivity of vaccinia by limiting viral replication to transformed cells. hGM-CSF expression by this agent may help recruit antigen processing cells (APCs), such as denritic cells and macrophages, to virally infected tumor cells, initiating a systemic antitumoral immune response (Moehler et al., 2019; NCIT_C71533).
|
| Host Response |
|
|
| References |
Aarntzen et al., 2012: Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(19); 5460-5470. [PubMed: 22896657].
Moehler et al., 2019: Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology. 2019; 8(8); 1615817. [PubMed: 31413923].
NCIT_C71533: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71533]
NCT02562755: Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS) [https://clinicaltrials.gov/ct2/show/NCT02562755]
|
|
